

Strengthening U.S. healthcare Supply Chain Resilience Through Data-Driven Strategies to Ensure Consistent Access to Essential Medicines

Samuel Ajibola Dada ^a, Jude Shagan Azai ^a, Jehoiarib Umoren ^b, Emmanuel Utomi ^c, and Benjamin Gyedu Akonor ^{d*}

^{d*} *benjaminakonor3@gmail.com*

^a *Whitman School of Management, Syracuse University, USA*

^b *C.T. Bauer College of Business, University of Houston, USA*

^c *Department of Computing and Informatics, College of Science, University of Louisiana at Lafayette, LA, USA.*

^d *Department of Chemistry, Kwame Nkrumah University of Science and Technology, Ghana*

Abstract

During the COVID-19 outbreak, the flaws in U.S. healthcare supply chains became apparent, especially concerning the availability of essential medicines. They highlighted the need for proactive and data-driven strategies to improve supply chain resilience. A lack of predictive systems, real-time inventory management, and supply chain transparency during the pandemic contributed to stockouts, increased costs, and compromised patient care in the absence of robust predictive systems, real-time inventory management, and supply chain transparency. This crisis offers lessons about the central importance of carrying out the strategies presented in this study. Technologies such as artificial intelligence, blockchain, and real-time inventory systems can revolutionize the healthcare supply chain and help stakeholders predict and mitigate disruptions before they become big. For instance, AI can help with demand forecasting while blockchain helps to prevent counterfeit medicines by enforcing transparency and traceability. However, these technologies only work as well as the systems and policies that support their use. To achieve resilience, policymakers must set clear regulatory frameworks that enable integration of new technologies to ensure patient security and data protection, support public-private partnerships to pilot new solutions and scale successful models nationally, fund modernization of legacy systems, strengthen data infrastructure, and invest in workforce development to close skills gaps. A future crisis can be prevented only when technology is aligned with policy through the collaborative efforts of all the stakeholders. The U.S. healthcare system can learn from the challenges of the pandemic and prioritize the application of data-driven strategies to move away from reactive crisis management to proactive resilience. It's not just a healthcare imperative – it's a key element of national security and public health.

Keywords: Healthcare Supply Chain; Essential Medicines; Data-Driven Strategies; Artificial Intelligence; Blockchain Technology

1. Introduction

The World Health Organization (WHO) defines essential medicines as pharmaceuticals that fulfill the essential healthcare needs of the community. The FDA has redefined this idea through its list of essential medicines, medical countermeasures, and critical inputs relevant to public health crises and national security [1]. Providing uninterrupted access to these important medicines is essential rather than just a convenience for

a well-functioning healthcare system and a resilient community. A reliable stock of essential medicines is very important. Insufficient supply can cause delays in treatment, errors with doses, and increased healthcare costs. As an example, a recent WHO report found that the number of global drug shortages has increased, and the impact of drug shortages far exceeds those who can bear them and exacerbate health inequality [2]. Shukar and coworkers reported that annual labor costs for U.S. hospitals due to drug shortages reached at least \$359 million. Critical drug shortages could weaken the nation's readiness to deal with health emergencies like the early chapters of the COVID-19 pandemic [3].

Given these issues, data-driven strategies stand out as a viable approach to improve supply chain resilience. Advanced technology such as artificial intelligence (AI) and machine learning (ML) in combination with blockchain enables possibilities to enhance supply chain operations, predict and prevent disruptions, and ensure a steady supply of essential medicines [4]. Data-driven strategies can reshape substantial portions of the healthcare supply chain. Predictive analytics can more surely predict demand, which helps manage inventory more effectively and lowers the chance of stock-outs. Through the analysis of substantial datasets from multiple sources, artificial intelligence (AI) and machine learning (ML) techniques can spot potential disruptions in the supply chain prior to their occurrence enabling proactive mitigation strategies. Blockchain has the ability to improve clarity and identify routes for products in supply chains to tackle counterfeit goods and ensure product integrity [5].

Significant benefits are expected from these technologies. According to a 2021 Accenture report, AI in the supply chain could lead to savings of up to \$10 billion each year for the healthcare industry [6]. In addition, greater visibility within the supply chain and forecasting capabilities could reduce medicine shortages by up to 30%, as predicted by the Healthcare Distribution Alliance [7]. However, there are challenges involved in executing these data-oriented methods. Existing systems require adjustment to meet the needs of addressing data quality and privacy. To meet the needs of tech changes, regulatory systems may need to improve to ensure patient safety and data security [8].

Existing literature investigates the weaknesses of global healthcare supply chains and provides examples of new data-driven approaches, but these are primarily for individual technologies, such as blockchain or predictive analytics, in isolation. The literature to date lacks a framework for integrating these technologies to support the challenges of the U.S. healthcare supply chain. This study aims to fill this gap by developing a holistic, data driven approach to improving the U.S. healthcare supply chain's resilience and ensuring uninterrupted access to essential medicines. This study aims to investigate and evaluate strategies that can reduce the supply chain disruption risks in the U.S. healthcare sector using data data-driven approach. Specifically, this research seeks to:

- Identify the existing challenges and bottlenecks in the U.S. healthcare supply chain, specifically for essential medicines.
- Analyze the potential use of data-driven technologies like artificial intelligence, predictive modeling, real-time inventory processes, and blockchain for enhancing supply chain resilience
- Examine case studies of successful deployment of these technologies and highlight lessons for wider adoption.
- Recommend actionable policies to spur the adoption of those strategies including dealing with barriers such as regulation, workforce readiness, and interoperability.

The goal of this study is to create a roadmap for healthcare ecosystem stakeholders to design a more robust, responsive, and sustainable supply chain, by addressing these objectives.

2. Literature review

2.1 Existing Challenges of the U.S. Healthcare Supply Chain

There are many challenges that hinder the efficiency and resilience of the U.S. healthcare supply chain.

Lack of transparency: A major problem is the lack of transparency throughout the supply chain. Various stakeholders act independently causing disputes in information distribution and inefficient decision-making [9]. This unclear structure limits accurate foresight and response strategies in the face of disruptions.

Global dependency: A major challenge lies in the high reliance on manufacturing sites in a few geographical locations such as China and India for critical active pharmaceutical ingredients (APIs). Together, these two countries are responsible for the supply of approximately 80% of APIs used in U.S. generic drugs [1]. For example, India is responsible for roughly 40% of generic drugs imported to the U.S. and China is the largest source of key raw materials and APIs needed to manufacture drugs [10]. This high concentration heightens the risk of regional disruptions and international tensions [11]. During the COVID-19 crisis in China factories closing led to disturbances in the worldwide pharmaceutical supply system [12].

Inventory practices: Inventory management creates another challenge. During normal times the just-in-time inventory method keeps costs down but significantly reduces opportunities for error in crises [13]. This method contributed to a major lack of PPE and particular medications early in the pandemic [14].

Regulatory complexities: Regulatory hurdles also pose challenges. If the approval times for new providers or production modifications are long enough, delays in responding to supply chain issues may occur [15]. Unstable global regulatory requirements make it difficult for businesses to source and distribute products across borders.

Lastly, the healthcare supply chain faces cybersecurity risks. As supply chains evolve into more digital environments, they allow for greater vulnerability to cyber-attacks that can compromise operations and endanger sensitive data [16]. Resolving these diverse challenges demands a collaborative and data-driven plan that involves all stakeholders in the healthcare supply chain setup.

2.2. Essential Medicines: Definition and Significance

Global health policy and implementation heavily depend on the idea of essential medicines. WHO identifies essential medicines as "those that satisfy the priority health care needs of the population" [2]. The selection of these medications is based on their public health relevance, effectiveness, and comparative cost-effectiveness. Before being introduced in 1977 and updated every other year the WHO Model List of Essential Medicines acts as a resource for creating essential medicine lists globally [17].

The Food and Drug Administration (FDA) has adopted this concept for the national situation in the United States. In 2020 the FDA introduced essential medicines and critical inputs due to both the COVID-19 pandemic and lingering concerns about supply chain stability [1]. The emphasis is on essential items needed for the timely care of patients and to secure public health in emergencies.

The importance of essential medicines goes well beyond their basic therapeutic value. They play a key role in medical systems along with security systems at the national level. The availability of essential medicines acts as an important measure of the quality and scope of a country's health system [18]. Regulating an uninterrupted flow of these treatments is important for controlling chronic diseases and rapid public health crises.

Essential medicines have a huge economic impact. While only a minor segment of the total pharmaceutical market exists, essential medicines play an important role in funding healthcare in developing nations [19]. In high-income nations such as the United States, essential medicines effectively control healthcare costs through their role as a benchmark for optimized resource management.

In public health terms, essential medicines are essential for tackling major health requirements for the populace. Primary healthcare, the management of major chronic diseases such as cardiovascular diseases and diabetes, and the treatment of infectious diseases including HIV/AIDS, tuberculosis, and malaria rely heavily

on them [20]. During health emergencies like COVID-19 essential medicines gain increased importance due to the worldwide rush for antiviral medications and vaccines [21].

However, with their critical importance, access to essential medicines in the United States remains an important challenge. The high cost of prescription drugs is one of the main problems. While prescription drug prices in the U.S. are, on average, 2.5 times higher than in other high-income countries, they have become increasingly unaffordable for many Americans, according to a 2022 report by the Commonwealth Fund [22]. The added insult of a lack of robust price regulation mechanisms is also contributed to by the fact that these prices are higher than those in other countries, where government negotiations or caps on drug prices are common [23].

In addition, access to essential medicines is uneven, with rural and low-income populations most affected. For example, rural hospitals generally incur higher logistical and inventory costs and greater risks of stockouts, due to the greater logistical challenge. Furthermore, financial barriers—imposing delay or denial of treatment for uninsured individuals and those with high deductible plans—are against health disparities [18].

Pricing, supply chain bottlenecks, and access challenges are all evidence of where systemic reforms are needed to make essential medicines available and affordable. To build such a healthcare system that equitably and consistently provides care to all Americans, these issues must be addressed.

3. Data-Driven Strategies for Supply Chain Resilience

This section delves into how advanced data analytics and new technologies can strengthen supply chains in the face of disruptions. At a time of global uncertainty, supply chains are challenged by natural disasters, geopolitical tensions, and more. Through the integration of real-time data, predictive analytics, and AI-driven insights, businesses can increase visibility, improve decision-making, and create adaptive systems that guarantee continuity and efficiency. Here, we discuss actionable frameworks and technologies that enable organizations to anticipate risks, respond to change quickly and maintain competitive advantage in a dynamic market.

3.1. Big Data Analytics

Modern supply chain planning relies heavily on big data analytics, especially for healthcare and critical pharmaceuticals. In this area, big data utilizes diverse sources such as sales data from pharmacies and healthcare providers, inventory levels in the supply chain, electronic health records (EHRs) for population trends, and social media for identifying outbreaks early. Through the merging and evaluation of multiple information streams organizations can establish a thorough perspective on the supply chain and enhance their strategic choices. The work of Moons and coworkers proved that big data analysis can anticipate drug shortages 12 months in advance [24]. Through the study of past shortages along with market trends and production complexities, their model reached more than 80% precision in forecasting future shortages of essential medicines. Big data tools boost the management of inventories. The work of Uthayakumar and Priyan demonstrated that applying data analytics to inventory helps cut costs by 30% while securing consistent service quality for pharmaceuticals [25].

3.2. Artificial Intelligence (AI) and Machine Learning (ML)

By recognizing complex patterns and making predictive forecasts beyond human cognitive capabilities, AI and machine learning amplify the potency of big data analytics. By analyzing historical and present data AI algorithms in the pharmaceutical supply chain can predict disruptions, optimize routing and logistics for

medicine distribution, and enhance demand forecasting accuracy. An important case of AI's influence is using reinforcement learning algorithms in managing inventory. Oroojlooyjadid and coworkers indicated that these algorithms outstripped typical inventory strategies in reducing stockouts and overstock for essential medicines [26]. In the changing healthcare context ML models play a crucial role since they continuously evolve and respond to shifts in conditions.

3.3. Predictive Modeling for Demand Forecasting

Predictive modeling, a key application of AI and ML, is crucial for demand forecasting in the healthcare supply chain. These models review different components such as previous sales trends, seasonal disease patterns, demographic changes, and the effects of economic factors on treatment access. By taking account of several aspects predictive models create more exact estimations for essential medication requirements. Predictive demands help keep stock levels steady and prevent shortages that can prolong treatment and oversupply, which might cause wasted goods with limited shelf-life. According to Yani and coworkers, forecasting models derived from machine learning achieved an improved accuracy of 15-20% versus conventional time-series methods for chronic medication prediction [27].

3.4. Real-time Inventory Management Systems

Systems for real-time inventory tracking using IoT information and cloud platforms provide unparalleled awareness of inventory levels in the supply chain. Often these systems incorporate Radio-frequency identification (RFID) tags and smart sensors on medication packaging and connect stores in warehouses and pharmacies through cloud-based systems. Evidence from this immediate monitoring fosters quicker reactions to changes in both supply and demand. Should a sudden rise in medication demand occur in a hospital, the system can instantly send new order requests or transfer available surplus from other locations. A major US healthcare system saw an improvement in staff productivity alongside a 54% reduction in drug expiries and a 25% drop in stockouts according to a GS1 (2019) study on the introduction of a real-time inventory management system (GS1, 2019).

3.5. Blockchain Technology

Blockchain technology can bring a probable solution to boost transparency and traceability in the pharmaceutical supply chain. It allows for validating the authenticity of drugs, tracking their path to patients, and providing complete feedback in handling and recalls. Blockchain produces a permanent and decentralized record of transactions that greatly minimizes the threat of counterfeit drugs reaching the supply chain while improving quality assurance. In 2019 Chronicled and The LinkLab executed a trial that exhibited how blockchain tech could fulfill the track-and-trace standards of the Drug Supply Chain Security Act (DSCSA) in the United States [29]. This model ensured full visibility of prescription medicines throughout their life cycle from the point of manufacture to the point of dispensing.

3.6. Advanced Risk Management Analytics

Advanced analytics play a vital role in supporting sophisticated risk management strategies within the healthcare supply chain. These analytics can assess supplier performance and reliability, monitor geopolitical events that might impact supply, evaluate the effects of natural disasters on manufacturing and distribution, and analyze the financial health of key supply chain partners. By leveraging these insights, organizations can

develop more robust contingency plans and more effectively diversify their supply sources. A study by Tucker et al. [30] demonstrated how network analysis techniques could identify critical nodes and potential vulnerabilities in the pharmaceutical supply chain, enabling more targeted risk mitigation strategies and enhancing overall resilience.

Artificial intelligence (AI) in the U.S. healthcare supply chain could be implemented to generate large cost savings. Broad adoption of AI in healthcare operations could save between 5 and 10% of spending, or \$200 billion to \$360 billion annually, according to estimates [31].

Although these data-driven strategies hold significant promise for improving supply chain resilience, their implementation faces challenges such as ensuring data quality and interoperability, addressing privacy and security concerns, and fostering collaboration among diverse healthcare supply chain stakeholders. Nonetheless, as technology advances and data become more accessible, these strategies will likely play a crucial role in ensuring consistent access to essential medicines and improving healthcare outcomes overall.

4. Challenges in Implementing Data-Driven Strategies

While data-driven strategies offer significant potential for improving healthcare supply chain resilience, their implementation is not without challenges. These obstacles must be addressed to fully realize the benefits of these innovative approaches.

4.1. Data Quality and Standardization

Addressing the issue of data consistency and quality presents a major challenge in the supply chain. Data related to healthcare frequently originates from multiple sources with inconsistent formats and standards difficult to integrate and analyze. Deficient data reliability causes unreliable predictions and unsatisfactory judgments. Establishing uniform data capture and management methods within the supply chain is vital; however, it generally needs considerable investment of both time and resources [32].

4.2. Privacy and Security Concerns

In healthcare practices, privacy and security of patient data take priority due to the sensitive nature of the information. Strategies based on data must be in line with regulations like HIPAA in the US or GDPR in Europe. Managing access to data in relation to privacy is a critical issue particularly when working with data from different contributors across the supply chain [33].

4.3. Integration with Legacy Systems

Many healthcare organizations depend on outdated systems that do not work with advanced data-driven technologies. Merging contemporary analysis tools with present ERP frameworks or EHR systems proves difficult and expensive [34].

4.4. Workforce Training and Adaptation

To execute data-oriented strategies teams must possess expertise in analytics and supply chain operations. A lack of talent in the healthcare field often occurs and calls for major resources for training and growth [35].

4.5. Regulatory Compliance

Regulations are tight in the healthcare field which demands that new data-centric solutions fit into the current framework. Implementing such breakthroughs can be difficult for innovative tools like AI and blockchain as rules still evolve [36].

4.6. Interoperability Issues

For effective execution of data-driven strategies, it is necessary to have uninterrupted data sharing among the different systems and participants in the supply chain. Navigating the complicated healthcare field to attain interoperability is still a major issue [37].

To overcome these issues all stakeholders in the healthcare supply chain must work together. The benefits of data-focused strategies in making sure essential medicine access remains constant outweigh the hurdles we face.

5. Policy Recommendations and Future Directions

To fully utilize data driven strategies for improving healthcare supply chain resilience there is a need to focus on targeted actions. Specific regulatory updates, collaboration among key organizations and investments in technological and workforce development are some of them.

5.1 Policy recommendations

Several policy recommendations need to be prioritized to help enhance the resilience of the healthcare supply chain. First things first, standardization is a must. For supply chain operations, an industry wide approach to data standards is needed, for example, expanding the use of the HL7's FHIR (Fast Healthcare Interoperability Resources) framework [38]. Better data integration across sectors will be enabled. The adoption of these standards must be widespread, and so key stakeholders like the Office of the National Coordinator for Health Information Technology (ONC), the FDA and healthcare industry organizations such as GS1 must work together to achieve this.

Important too are regulatory framework updates to keep up with new technologies like AI, blockchain and IoT. These technologies have to be either integrated into the supply chain, while ensuring safety and compliance. With the implementation of the FDA's Drug Supply Chain Security Act (DSCSA), scope should additionally extend to advanced technology that allows for improved traceability, such as blockchain. Moreover, guidelines should be set down to ensure the ethical use of AI — such as algorithm transparency and accountability. Similarly, during public health emergencies, the approval process for new suppliers and manufacturing methods should be streamlined to provide for rapid responses to shortages. These updates will be led by the FDA, but ONC and the National Institute of Standards and Technology (NIST) will be involved as well by creating standards and cyber security protocols.

A critical strategy in fostering public-private partnerships is also instrumental. The pilot of innovative supply chain solutions should be encouraged by collaborations between government agencies, private technology companies and healthcare providers. As a model for scaling such technologies across the entire industry, for example, the FDA's ongoing blockchain pilot projects under the DSCSA could be a useful example. In this sense, HHS, pharmaceutical manufacturers and distributors should be the main stakeholders.

Infrastructure investment is also equally important. Healthcare organizations should be offered tax incentives and grants by federal and state governments to update legacy systems, to implement real time inventory management platforms and to use cloud-based analytics tools. They will help to build an efficient

and flexible healthcare supply chain. Although these are not paid, private companies can also participate by means of cost sharing models to relieve the financial burden.

Workforce development comes last. To close the supply chain skills gap, it'll be critical to create certifications and degree programs in healthcare supply chain analytics and data governance. Federal funding and industry partnership should be used to support these programs. Academic institutions and professional organizations, such as the Association for Supply Chain Management (ASCM) and healthcare employers should collaborate to prepare the workforce for future demands of a data driven healthcare system.

5.2 Future directions

We are on the verge of deeply embedding AI within the healthcare supply chain, using sophisticated predictive analytics and automated decision making. For example, AI can be used to forecast supply disruptions, based on global trade and weather patterns. Doing so allows stakeholders to proactively prevent disruptions from escalating, to keep essential medicines available and accessible.

Blockchain technology has the potential to provide wider adoption and revolutionize traceability and transparency of the healthcare supply chain. An immutable record of transactions, blockchain's decentralized nature also means that we can track medicines from manufacturer to patient. Expanding the scope of pilot projects like MediLedger, which focuses so far on high-value drugs, to all essential medicines means that these critical products would be subject to the same level of traceability and transparency.

By computing data closer to its source, edge computing can improve real-time decision-making significantly, by processing data within hospitals or warehouses for example. One example is edge computing to monitor temperature sensitive medicines in transit, keeping the conditions optimal and eliminating spoilage. The ability to maintain vaccine and biologics at the appropriate temperature at all points of the supply chain is especially important.

Environmental sustainability will eventually become a key future healthcare supply chain strategy. By using AI to optimize delivery routes, not only would we improve delivery route efficiency but also decrease carbon footprints and operational costs. This is in line with broader goals of creating a less wasteful supply chain that has little impact on the environment when transporting medicines.

The regulatory updates are led by the FDA, but systemic change requires more. This is the role of the FDA on drug safety, quality, and traceability initiatives. By setting standards for data interoperability between healthcare systems, the ONC guarantees the possibility of a smooth transition of data between several healthcare stakeholders. With cyber security frameworks provided by NIST, sensitive supply chain data is protected, and information is kept secure. National strategies for healthcare infrastructure investment are coordinated by the HHS; state governments carry out local implementation of federal guidelines and offer funding incentives. Meeting these regulatory, technological, and organizational needs will help stakeholders build a resilient healthcare supply chain that enables continuity of access to critical medicines in the face of future challenges and innovation.

6. Conclusion

For public safety and health well-being, essential medicines need strong healthcare supply chains. Data-driven strategies offer powerful tools to address longstanding challenges in this domain. Stakeholders can improve forecasting for demand while boosting inventory management and enhancing transparency in supply chains by using advanced technologies like big data analytics and AI. Even with numerous challenges to implementation like quality data issues and the need for workforce development, the advantages are substantial. As we move forward, a concerted effort from policymakers, healthcare providers, and technology

companies will be essential to fully realize the potential of these strategies. Utilizing data-focused techniques helps us to construct a more robust, efficient, and responsive healthcare supply chain ensuring every individual receives essential medicines consistently.

References

- [1] U.S. Food and Drug Administration. (2020). Executive Order 13944: List of essential medicines, medical countermeasures, and critical inputs. Retrieved from <https://www.fda.gov/about-fda/reports/executive-order-13944-list-essential-medicines-medical-countermeasures-and-critical-inputs>
- [2] World Health Organization. (2023). WHO Model List of Essential Medicines - 23rd list, 2023. World Health Organization. <https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02>
- [3] Shukar, S., Zahoor, F., Hayat, K., Saeed, A., Gillani, A. H., Omer, S., ... & Yang, C. (2021). Drug shortage: causes, impact, and mitigation strategies. *Frontiers in pharmacology*, 12, 693426.
- [4] Srinivasan, R., & Swink, M. (2018). An investigation of visibility and flexibility as complements to supply chain analytics: An organizational information processing theory perspective. *Production and Operations Management*, 27(10), 1849-1867.
- [5] Clauson, K. A., Breeden, E. A., Davidson, C., & Mackey, T. K. (2018). Leveraging blockchain technology to enhance supply chain management in healthcare. *Blockchain in Healthcare Today*, 1, 1-12.
- [6] Accenture. (2021). AI: Built to Scale. From experimental to exponential.
- [7] Healthcare Distribution Alliance. (2019.). *The role of distributors in the U.S. health care industry*. Healthcare Distribution Alliance. <https://www.hda.org/publications/the-role-of-distributors-in-the-us-health-care-industry-8210cd8c1b20adf4d87db4f48b2503d/>
- [8] Kuo, T. T., Kim, H. E., & Ohno-Machado, L. (2017). Blockchain distributed ledger technologies for biomedical and health care applications. *Journal of the American Medical Informatics Association*, 24(6), 1211-1220.
- [9] Dai, T., Bai, G., & Anderson, G. F. (2020). PPE Supply Chain Needs Data Transparency and Stress Testing. *Journal of General Internal Medicine*, 35(9), 2748-2749.
- [10] ASPE (2022). Office of the Assistant Secretary for Planning and Evaluation. *U.S. reliance on foreign pharmaceutical supply chains*. Retrieved from <https://aspe.hhs.gov>
- [11] Mullin, R. (2020). COVID-19 is reshaping the pharmaceutical supply chain. *Chemical & Engineering News*, 98(16).
- [12] Handfield, R., Finkenstadt, D. J., Schneller, E. S., Godfrey, A. B., & Guinto, P. (2020). A commons for a supply chain in the post-COVID-19 era: The case for a reformed strategic national stockpile. *The Milbank Quarterly*, 98(4), 1058-1090
- [13] Durugbo, C. M., & Al-Balushi, Z. (2023). Supply chain management in times of crisis: a systematic review. *Management Review Quarterly*, 73(3), 1179-1235.
- [14] Patel, A., D'Alessandro, M. M., Ireland, K. J., Burel, W. G., Wencil, E. B., & Rasmussen, S. A. (2017). Personal protective equipment supply chain: lessons learned from recent public health emergency responses. *Health security*, 15(3), 244-252.
- [15] Woodcock, J., & Wosinska, M. (2013). Economic and technological drivers of generic sterile injectable drug shortages. *Clinical Pharmacology & Therapeutics*, 93(2), 170-176.
- [16] Wright, J. (2023). Healthcare cybersecurity and cybercrime supply chain risk management.
- [17] Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., De Joncheere, C. P., Ewen, M. A., ... & Reich, M. R. (2017). Essential medicines for universal health coverage. *The Lancet*, 389(10067), 403-476.
- [18] Persaud, N., Jiang, M., Shaikh, R., Bali, A., Oronsaye, E., Woods, H., ... & Tricco, A. C. (2019). Comparison of essential medicines lists in 137 countries. *Bulletin of the World Health Organization*, 97(6), 394.
- [19] Beran, D., Ewen, M., & Laing, R. (2016). Constraints and challenges in access to insulin: a global perspective. *The lancet Diabetes & endocrinology*, 4(3), 275-285
- [20] Bigdeli, M., Jacobs, B., Tomson, G., Laing, R., Ghaffar, A., Dujardin, B., & Van Damme, W. (2013). Access to medicines from a health system perspective. *Health policy and planning*, 28(7), 692-704.
- [21] Iyengar, S., Hedman, L., Forte, G., & Hill, S. (2016). Medicine shortages: a commentary on causes and mitigation strategies. *BMC medicine*, 14(1), 1-3.
- [22] Commonwealth Fund (2022). U.S. Prescription Drug Prices Are 2.5 Times Higher Than Other Nations. Retrieved from <https://www.commonwealthfund.org>
- [23] Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States: origins and prospects for reform. *Jama*, 316(8), 858-871.
- [24] Moons, K., Waeyenbergh, G., & Pintelon, L. (2019). Measuring the logistics performance of internal hospital supply chains – A literature study. *Omega*, 82, 205-217.
- [25] Uthayakumar, R., & Priyan, S. (2013). Pharmaceutical supply chain and inventory management strategies: Optimization for a pharmaceutical company and a hospital. *Operations Research for Health Care*, 2(3), 52-64.
- [26] Oroojlooyjadid, A., Snyder, L. V., & Takáč, M. (2020). Applying deep learning to the newsvendor problem. *IIE Transactions*, 52(4), 444-463.
- [27] Yani, L. P. E., & Aamer, A. (2023). Demand forecasting accuracy in the pharmaceutical supply chain: a machine learning approach. *International Journal of Pharmaceutical and Healthcare Marketing*, 17(1), 1-23.

- [28] GS1. (2019). Mercy ROI Case Study: Inventory Management. Retrieved from <https://www.gs1us.org/>
- [29] MediLedger. (2019). DSCSA FDA Pilot Project. Retrieved September 29, 2024, from <https://www.mediledger.com/dscsa-fda-pilot-project>
- [30] Tucker, E. L., Daskin, M. S., Sweet, B. V., & Hopp, W. J. (2020). Incentivizing resilient supply chain design to prevent drug shortages: Policy analysis using two- and multi-stage stochastic programs. *IIE Transactions*, 52(4), 394-412.
- [31] National Bureau of Economic Research. (2024). *The potential impact of artificial intelligence on healthcare spending*. Retrieved from <https://www.nber.org>
- [32] Hasan, R., Kamal, M. M., Daowd, A., Eldabi, T., Koliouis, I., & Papadopoulos, T. (2024). Critical analysis of the impact of big data analytics on supply chain operations. *Production Planning & Control*, 35(1), 46-70.
- [33] Patil, H. K., & Seshadri, R. (2019). Big data security and privacy issues in healthcare. 2014 IEEE International Congress on Big Data, 762-765.
- [34] Aceto, G., Persico, V., & Pescapé, A. (2018). The role of Information and Communication Technologies in healthcare: taxonomies, perspectives, and challenges. *Journal of Network and Computer Applications*, 107, 125-154.
- [35] Wamba, S. F., Gunasekaran, A., Dubey, R., & Ngai, E. W. (2018). Big data analytics in operations and supply chain management. *Annals of Operations Research*, 270(1-2), 1-4.
- [36] D'souza, S., Nazareth, D., Vaz, C., & Shetty, M. (2021, May). Blockchain and AI in pharmaceutical supply chain. In *Proceedings of the International Conference on Smart Data Intelligence (ICSMDI 2021)*.
- [37] He, J., Baxter, S. L., Xu, J., Xu, J., Zhou, X., & Zhang, K. (2019). The practical implementation of artificial intelligence technologies in medicine. *Nature Medicine*, 25(1), 30-3
- [38] HL7 International (FHIR Framework). Fast Healthcare Interoperability Resources (FHIR). Retrieved from <https://hl7.org/fhir>